# A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)

Source: https://onco.cc/trials/nct06644781/  
OnCo record `nct06644781` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Ifinatamab deruxtecan and Docetaxel in oesophageal cancer, run by Daiichi Sankyo, now recruiting.

## Summary

A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) is a phase 3 interventional study registered as NCT06644781 by Daiichi Sankyo, with 510 participants planned, started 2025-03-27 and due to reach its primary completion in 2028-06-01. Interventions recorded: Ifinatamab deruxtecan, Docetaxel, Paclitaxel and Irinotecan hydrochloride (HCl).

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06644781
- Phase: 3
- Setting: A Phase 3, Multicenter, Randomized, Open-label Study of Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
- Sponsor: Daiichi Sankyo
- Enrolled: 510

## Sources

- ClinicalTrials.gov NCT06644781: https://clinicaltrials.gov/study/NCT06644781

## Connected records

- cancers: [Oesophageal cancer](https://onco.cc/cancers/esophageal/)
- drugs: [Docetaxel](https://onco.cc/drugs/docetaxel/), [Ifinatamab deruxtecan](https://onco.cc/drugs/ifinatamab-deruxtecan/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/), [Merck & Co. (MSD)](https://onco.cc/companies/merck/)

---
JSON: https://onco.cc/api/v1/entities/nct06644781.json